Last reviewed 2026-04-23 · How we verify

EDP-323 Dose Regimen 1

Enanta Pharmaceuticals, Inc · Phase 2 active Small molecule

EDP-323 Dose Regimen 1 is a Small molecule drug developed by Enanta Pharmaceuticals, Inc. It is currently in Phase 2 development.

At a glance

Generic name	EDP-323 Dose Regimen 1
Sponsor	Enanta Pharmaceuticals, Inc
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EDP-323 Dose Regimen 1 CI brief — competitive landscape report
EDP-323 Dose Regimen 1 updates RSS · CI watch RSS
Enanta Pharmaceuticals, Inc portfolio CI

Frequently asked questions about EDP-323 Dose Regimen 1

What is EDP-323 Dose Regimen 1?

EDP-323 Dose Regimen 1 is a Small molecule drug developed by Enanta Pharmaceuticals, Inc.

Who makes EDP-323 Dose Regimen 1?

EDP-323 Dose Regimen 1 is developed by Enanta Pharmaceuticals, Inc (see full Enanta Pharmaceuticals, Inc pipeline at /company/enanta-pharmaceuticals-inc).

What development phase is EDP-323 Dose Regimen 1 in?

EDP-323 Dose Regimen 1 is in Phase 2.

Manufacturer: Enanta Pharmaceuticals, Inc — full pipeline
Compare: EDP-323 Dose Regimen 1 vs similar drugs
Pricing: EDP-323 Dose Regimen 1 cost, discount & access